Frequency of clonal remission in acute myeloid leukaemia.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood (2014) 2.54

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03

Clonality of CD3 negative large granular lymphocyte proliferations determined by PCR based X-inactivation studies. J Clin Pathol (1994) 0.79

Preleukemia: One name, many meanings. Leukemia (2016) 0.75

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood (2001) 5.34

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood (2001) 5.20

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet (1993) 3.36

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood (2001) 2.61

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30

Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol (1999) 2.24

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant (2003) 2.19

Amplification of mitochondrial DNA in acute myeloid leukaemia. Br J Haematol (1996) 2.17

Investigation and management of pulmonary infiltrates following bone marrow transplantation: an eight year review. Thorax (1993) 2.08

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol (1997) 2.02

Hepatitis B transmission from contaminated cryopreservation tank. Lancet (1995) 1.99

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98

A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood (1999) 1.97

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93

Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor. Nature (1985) 1.89

Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol (1997) 1.83

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet (2003) 1.80

Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood (1997) 1.73

Emotional support for cancer patients: what do patients really want? Br J Cancer (1996) 1.72

The macrophage electrophoretic migration test in cancer. Clin Exp Immunol (1973) 1.71

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet (1990) 1.71

Dielectrophoretic separation and enrichment of CD34+ cell subpopulation from bone marrow and peripheral blood stem cells. Med Biol Eng Comput (1995) 1.68

Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood (1999) 1.68

The dielectrophoresis enrichment of CD34+ cells from peripheral blood stem cell harvests. Bone Marrow Transplant (1996) 1.65

Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993. J Clin Oncol (1994) 1.63

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia (2005) 1.61

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol (2001) 1.58

The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood (1993) 1.55

ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia (2002) 1.54

Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med (1984) 1.54

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet (1998) 1.52

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia (2008) 1.50

Human macrophage colony-stimulating factor levels are elevated in pregnancy and in immune thrombocytopenia. Blood (1992) 1.49

CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia (2007) 1.49

Fc gamma RII, but not erythropoietin or GM-CSF, mediates calcium mobilization in fetal hemopoietic blast cells. Exp Hematol (1992) 1.45

Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet (1982) 1.45

Lack of effect of granulocyte-macrophage and granulocyte colony-stimulating factors on cultured human endothelial cells. Blood (1991) 1.43

G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol (1997) 1.42

Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol (1987) 1.42

Investigation of early T cell activation: analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentration. Eur J Immunol (1985) 1.41

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer (2001) 1.40

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail (2002) 1.40

Cavernosal arterial insufficiency and erectile dysfunction in recipients of high-dose chemotherapy and total body irradiation for multiple myeloma. Lancet (2000) 1.39

Third party mediated graft rejection despite irradiation of blood products. Br J Haematol (1992) 1.39

Transplantation in first remission of acute myeloid leukemia. N Engl J Med (1998) 1.39

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol (1996) 1.39

X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females. Br J Haematol (1991) 1.39

Acute-phase response in patients given rhIL-3 after chemotherapy. Lancet (1992) 1.39

Peripheral blood progenitor cells versus bone marrow. J Hematother (1994) 1.38

Tissue specificity of X-chromosome inactivation patterns. Blood (1994) 1.37

Reduced prostacyclin activity in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.34

Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood (1999) 1.33

Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood (1996) 1.30

CD2 and CD3 antigens mobilize Ca2+ independently. Eur J Immunol (1986) 1.29

Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet (1980) 1.29

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (1995) 1.29

Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia (2007) 1.29

Phenotypic analysis of fetal blood leucocytes: potential for prenatal diagnosis of immunodeficiency disorders. Prenat Diagn (1982) 1.28

Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol (1994) 1.28

IgA and IgM cytoplastic inclusions in a series of cases of chronic lymphocytic leukaemia. Clin Exp Immunol (1976) 1.26

Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease. Blood (2001) 1.24

Alleles at D6S265 and D6S105 define a haemochromatosis-specific genotype. Br J Haematol (1994) 1.23

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia (2007) 1.22

Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood (1996) 1.21

Signal transduction in human T lymphocytes. Immunol Rev (1987) 1.21

High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia (2007) 1.18

Differentiation linked expression of p28,33 (Ia-like) structures on human leukaemic cells. Br J Haematol (1977) 1.18

Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood (1989) 1.17

Different pathways of human T-cell activation revealed by PHA-P and PHA-M. Immunology (1986) 1.16

T cell receptor gene rearrangements define a monoclonal T cell proliferation in patients with T cell lymphocytosis and cytopenia. Blood (1986) 1.15

High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia (2006) 1.14

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant (2008) 1.14

Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol (2000) 1.14

Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol (1999) 1.13

Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother (1991) 1.13

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol (1999) 1.12

Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol (2001) 1.12